Switch theme
Sign up to access all valuation multiples
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
2013
172
LTM Revenue $65.6M
LTM EBITDA -$99.8M
-$43.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Voyager Therapeutics has a last 12-month revenue (LTM) of $65.6M and a last 12-month EBITDA of -$99.8M.
In the most recent fiscal year, Voyager Therapeutics achieved revenue of $80.0M and an EBITDA of -$78.6M.
Voyager Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Voyager Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $65.6M | XXX | $80.0M | XXX | XXX | XXX |
| Gross Profit | $65.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$99.8M | XXX | -$78.6M | XXX | XXX | XXX |
| EBITDA Margin | -152% | XXX | -98% | XXX | XXX | XXX |
| EBIT | -$103M | XXX | -$83.3M | XXX | XXX | XXX |
| EBIT Margin | -157% | XXX | -104% | XXX | XXX | XXX |
| Net Profit | -$86.6M | XXX | -$65.0M | XXX | XXX | XXX |
| Net Margin | -132% | XXX | -81% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Voyager Therapeutics's stock price is $3.
Voyager Therapeutics has current market cap of $151M, and EV of -$43.0M.
See Voyager Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$43.0M | $151M | XXX | XXX | XXX | XXX | $-1.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Voyager Therapeutics has market cap of $151M and EV of -$43.0M.
Voyager Therapeutics's trades at -0.5x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Voyager Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Voyager Therapeutics has a P/E ratio of -1.7x.
See valuation multiples for Voyager Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $151M | XXX | $151M | XXX | XXX | XXX |
| EV (current) | -$43.0M | XXX | -$43.0M | XXX | XXX | XXX |
| EV/Revenue | -0.7x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | 2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVoyager Therapeutics's last 12 month revenue growth is -15%
Voyager Therapeutics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.9M for the same period.
Voyager Therapeutics's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Voyager Therapeutics's rule of X is -191% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Voyager Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -152% | XXX | -98% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | -114% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -191% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 159% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 204% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Voyager Therapeutics acquired XXX companies to date.
Last acquisition by Voyager Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Voyager Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Voyager Therapeutics founded? | Voyager Therapeutics was founded in 2013. |
| Where is Voyager Therapeutics headquartered? | Voyager Therapeutics is headquartered in United States of America. |
| How many employees does Voyager Therapeutics have? | As of today, Voyager Therapeutics has 172 employees. |
| Who is the CEO of Voyager Therapeutics? | Voyager Therapeutics's CEO is Dr. Alfred W. Sandrock, Jr,M.D.,PhD. |
| Is Voyager Therapeutics publicy listed? | Yes, Voyager Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Voyager Therapeutics? | Voyager Therapeutics trades under VYGR ticker. |
| When did Voyager Therapeutics go public? | Voyager Therapeutics went public in 2015. |
| Who are competitors of Voyager Therapeutics? | Similar companies to Voyager Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Voyager Therapeutics? | Voyager Therapeutics's current market cap is $151M |
| What is the current revenue of Voyager Therapeutics? | Voyager Therapeutics's last 12 months revenue is $65.6M. |
| What is the current revenue growth of Voyager Therapeutics? | Voyager Therapeutics revenue growth (NTM/LTM) is -15%. |
| What is the current EV/Revenue multiple of Voyager Therapeutics? | Current revenue multiple of Voyager Therapeutics is -0.7x. |
| Is Voyager Therapeutics profitable? | Yes, Voyager Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Voyager Therapeutics? | Voyager Therapeutics's last 12 months EBITDA is -$99.8M. |
| What is Voyager Therapeutics's EBITDA margin? | Voyager Therapeutics's last 12 months EBITDA margin is -152%. |
| What is the current EV/EBITDA multiple of Voyager Therapeutics? | Current EBITDA multiple of Voyager Therapeutics is 0.4x. |
| What is the current FCF of Voyager Therapeutics? | Voyager Therapeutics's last 12 months FCF is -$63.4M. |
| What is Voyager Therapeutics's FCF margin? | Voyager Therapeutics's last 12 months FCF margin is -97%. |
| What is the current EV/FCF multiple of Voyager Therapeutics? | Current FCF multiple of Voyager Therapeutics is 0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
